酸酸乳ssr网站

hammer官网加速器-hammer加速器安全-hammer最新版app

酸酸乳免费SS/SSR节点账号及链接分享-每日福利(2021/4/27 ...:2021-4-27 · 说明：每日福利-免费ssr节点双账号众及ss节点链接同时共享，ssr节点账号及链接更新于2021年4月27日12时38分。此酸酸乳节点账号有效期不定，此香港节点账号延迟低，速度比之前的快一些。本站所分享的资源节点仅是帮助大家科学上网在Google上查 ...

Read more

hammer官网加速器-hammer加速器安全-hammer最新版app

We are in the pre-clinical phases of a new paradigm for the treatment of Pulmonary Arterial Hypertension (PAH), addressing the underlying causes of the disease.

酸酸乳节点分享网站
ssr节点2022每日更新

hammer官网加速器-hammer加速器安全-hammer最新版app

There is a pressing unmet need for more effective treatments of Pulmonary Arterial Hypertension. A progressive disease caused by cell proliferation in lung blood vessels, PAH (high blood pressure in lung arteries) can adversely affect the heart.
More

hammer官网加速器-hammer加速器安全-hammer最新版app

We have developed a new class of inhalable drugs to decrease cell proliferation, instead of merely “relaxing” pulmonary arteries as today’s vasodilators do. Our hope after clinical trials is to prove greater efficacy with fewer side effects.
More
酸酸乳节点网站

hammer官网加速器-hammer加速器安全-hammer最新版app

In solving the unique problems of our own pulmonary drug research, Pulmokine has developed patented inhalation systems and preclinical efficacy solutions that we are making available to the pulmonary drug development community.
酸酸乳节点网站

hammer官网加速器-hammer加速器安全-hammer最新版app

Pulmokine is interested in strategic partnerships with leading pharmaceutical corporations, R&D firms, licensors and/or investors to take our breakthrough technologies into the next phases of clinical development.
Contact us

© 2013 Pulmokine. All Rights Reserved.
A pharmaceutical company developing new treatments for Pulmonary Hypertension.
挂梯子加速器app  免费v.p.n加速器  星火海外版关闭购物授权码  hammer加速器  红杏加速器官方  swarm蜜蜂加速器  Twitter加速器免费